Economic evaluation of atezolizumab in combination with bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer in China: A cost-effectiveness analysis
Shuo Yang, Yibing Hou, Xiaohui Wang, Shuo Kang, Zhenhua Pan · 2026
Read Economic evaluation of atezolizumab in combination with bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer in China: A cost-effectiveness analysis by Shuo Yang, Yibing Hou, Xiaohui Wang, Shuo Kang, Zhenhua Pan (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0351029.txt.
Description
Shuo Yang and colleagues weighed cost against health gain for a three drug mix in advanced cervical cancer in China. The mix adds two targeted drugs to standard chemotherapy. Using trial survival data, they built a model that follows patients in three week steps over ten years and counts costs, years lived, and quality adjusted years.
The mix added about half a quality adjusted year, but at a very high extra cost. Cost per added quality year came to many times what China counts as good value. Extra checks on uncertain inputs did not change the verdict. From a public payer view, the authors conclude the mix does not give value for money at current prices.
Catalog record
| CREATOR | Shuo Yang, Yibing Hou, Xiaohui Wang, Shuo Kang, Zhenhua Pan |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 20848 |
| LICENSE | CC_BY |
| RIGHTS | CC BY |
| SOURCE | PLOS |